Experiences from other countries have shown that severe allergic reactions (anaphylaxis) to the novel COVID-19 vaccinations are occurring at an unprecedented rate. Albeit rare, these anaphylactic reactions often occur at the first dose after COVID-19 vaccinations and can be life-threatening.  Therefore, COVID-19 vaccines are currently restricted from at-risk patients with a history of severe allergic reactions. Utilising state-of-the-art clinical and laboratory allergy testing, HKU Department of Medicine will pilot the territory's first COVID-19 vaccine allergy protocol to study how to best facilitate at-risk patients to safely receive the COVID-19 vaccinations.